Yüklüyor......
An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics
Pomalidomide is an immunomodulatory drug and the dosage of 4 mg per day taken orally on days 1‐21 of repeated 28‐day cycles has been approved in the European Union and United States to treat patients with relapsed/refractory multiple myeloma. Because pomalidomide is extensively metabolized prior to...
Kaydedildi:
| Yayımlandı: | Clin Pharmacol Drug Dev |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6585766/ https://ncbi.nlm.nih.gov/pubmed/29746728 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.470 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|